RLAY Stock Analysis: Buy, Sell, or Hold?
RLAY - Relay Therapeutics, Inc. Common Stock
$12.78
-0.44 (-3.33%)
▼
5d:
+2.16%
30d:
-17.5%
90d:
+45.06%
BUY
HIGH Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 05, 2026
0d
Smart Money Accumulation
RLAY is down 3.3% this week, but smart money is accumulating calls. Top strike: $17 2026-06-18 with 6,227 OI. Call ratio: 91% View Scanner →
Strength: 5.8/10
Get Alerted When RLAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: RLAY shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: RLAY shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: RLAY is currently trading at $12.78, which is considered slightly low relative to its 30-day fair value range of $12.72 to $15.62.
Technical Outlook: Technically, RLAY is in a strong uptrend. Immediate support is located at $11.75, while resistance sits at $13.47. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.00 (+64.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RLAY is in a strong uptrend. Immediate support is located at $11.75, while resistance sits at $13.47. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.00 (+64.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$12.72 -
$15.62
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 64.3% below Wall St target ($21.00)
Trading Range Analysis
30-Day Trading Range
$12.72 -
$15.62
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$11.75
Resistance Level
$13.47
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.41
Wall Street Target
$21.00
(+64.3%)
Revenue Growth (YoY)
-60.9%
Share & Embed Analysis
Last updated: May 14, 2026 8:16 PM ET
Data refreshes hourly during market hours. Next update: 9:16 PM
Data refreshes hourly during market hours. Next update: 9:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RLAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Thomas Catinazzo
SELL
1800 shares
2026-04-09
Thomas Catinazzo
SELL
17717 shares
2026-04-07
Donald A Bergstrom
SELL
2686 shares
2026-01-28
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$23 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 58 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$208 | 49 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 63 BUY |
